LIXTE Biotechnology Advances LB-100 Cancer Trials in Collaboration with GSK and Roche

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT, LIXTW), a clinical-stage pharmaceutical company developing novel cancer therapies, has provided an update on its ongoing clinical trials for LB-100. The drug is being studied in collaboration with two global pharmaceutical leaders, GSK and Roche, for its potential in treating ovarian and colorectal cancer.

According to LIXTE’s President and CEO, Bas van der Baan, LB-100 has demonstrated tolerability and anti-cancer activity in clear cell ovarian cancer patients, reinforcing the company’s commitment to innovative oncology solutions. The ovarian cancer trials are currently underway at M.D. Anderson Cancer Center and Northwestern University with GSK’s support, while the colorectal cancer trial is being conducted at the Netherlands Cancer Institute, backed by Roche.

These collaborations mark a significant step in LIXTE’s mission to enhance chemotherapy and immunotherapy effectiveness, offering hope for improved cancer treatment options.